Lung Cancer
Conference Coverage
First-line nivolumab plus platinum/etoposide effective in extensive-stage SCLC
From the Journals
Clinicians still unaware of need for genetic testing in NSCLC
Most clinicians surveyed estimated that fewer than 50% of non–small cell lung cancer patients in their country undergo molecular testing.
Conference Coverage
Adjuvant osimertinib extends DFS in localized NSCLC
Osimertinib reduced the risk of disease recurrence or death by 79% in patients with EGFR-mutated non–small cell lung cancer.
Conference Coverage
Active cancer increases death risk in patients with COVID-19
News from the FDA/CDC
Frontline nivo-ipi plus chemo approved for metastatic NSCLC
News from the FDA/CDC
FDA approves brigatinib and companion diagnostic for NSCLC
Feature
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
Multiple factors helped keep the anticipated COVID-19 surge manageable at the hematologic oncology service of Levine Cancer Institute.
From the Journals
Low-dose erlotinib seems feasible for frail, elderly patients with NSCLC
The disease control rate was 90%, the median progression-free survival was 9.3 months, and few patients required treatment modifications.
News
Oncologists’ income and satisfaction are up
News from the FDA/CDC
FDA expands approval of atezolizumab in NSCLC
–s...
From the Journals
Tumor molecular profiling may help identify ‘exceptional responders’